HIV replication, inflammation, and the effect of starting antiretroviral therapy on plasma asymmetric dimethylarginine, a novel marker of endothelial dysfunction

Journal of Acquired Immune Deficiency Syndromes

Volumn 60, Issue 2, 2012, Pages 128-134

  Baker, Jason V ^a,b   Neuhaus, Jacqueline ^c   Duprez, Daniel ^a   Freiberg, Matthew ^d   Bernardino, Jose I ^e   Badley, Andrew D ^f   Nixon, Daniel E ^g   Lundgren, Jens D ^h   Tracy, Russell P ⁱ   Neaton, James D ^j  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b HENNEPIN COUNTY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MINNESOTA   (United States)

^d UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^e HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^f MAYO CLINIC   (United States)

^g VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h UNIVERSITY OF COPENHAGEN   (Denmark)

ⁱ UNIVERSITY OF VERMONT   (United States)

^j UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

more..

Author keywords

Antiretroviral therapy; Asymmetric dimethylarginine (ADMA); CD40 ligand; Endothelial dysfunction; HIV infection; Inflammation; P selectin

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; C REACTIVE PROTEIN; CD40 LIGAND; D DIMER; EFAVIRENZ; INTERLEUKIN 6; LAMIVUDINE PLUS ZIDOVUDINE; N(G),N(G) DIMETHYLARGININE; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PADGEM PROTEIN; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; EARLY INTERVENTION; ENDOTHELIAL DYSFUNCTION; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFLAMMATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; VIRUS REPLICATION;

ADULT; ANTI-HIV AGENTS; ANTIGENS, CD40; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARGININE; BIOLOGICAL MARKERS; FEMALE; HIV INFECTIONS; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; P-SELECTIN; PLASMA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; VIRUS REPLICATION;

EID: 84862155139     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318252f99f     Document Type: Article

References (39)

1. Neuhaus J, Jacobs DR Jr, Baker JV, et al. Markers of inflammation, coagulation, and renal function are elevated in adults with HIV infection.J Infect Dis. 2010;201:1788-1795.
2. Kuller LH, Tracy R, Belloso W, et al. Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med.2008;5:e203.
3. Baker JV, Neuhaus J, Duprez D, et al. Changes in inflammatory and coagulation biomarkers: a randomized comparison of immediate versus deferred antiretroviral therapy in patients with HIV infection. J Acquir Immune Defic Syndr. 2011;56:36-43.
4. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood. 1998;91:3527-3561. (Pubitemid 28225719)
5. Blann AD. Endothelial cell activation, injury, damage and dysfunction: separate entities or mutual terms? Blood Coagul Fibrinolysis. 2000;11: 623-630.
6. Papasavvas E, Azzoni L, Pistilli M, et al. Increased soluble vascular cell adhesion molecule-1 plasma levels and soluble intercellular adhesion molecule-1 during antiretroviral therapy interruption and retention of elevated soluble vascular cellular adhesion molecule-1 levels following resumption of antiretroviral therapy. AIDS. 2008;22:1153-1161.
7. Calmy A, Gayet-Ageron A, Montecucco F, et al. HIV increases markers of cardiovascular risk: results from a randomized, treatment interruption trial. AIDS. 2009;23:929-939.
8. de Gaetano Donati K, Rabagliati R, Iacoviello L, et al. HIV infection, HAART, and endothelial adhesion molecules: current perspectives.Lancet Infect Dis. 2004;4:213-222. (Pubitemid 38407303)
9. Baker J, Ayenew W, Quick H, et al. High-density lipoprotein particles and markers of inflammation and thrombotic activity in patients with untreated HIV infection. J Infect Dis. 2010;201:285-292.
10. Melendez MM, McNurlan MA, Mynarcik DC, et al. Endothelial adhesion molecules are associated with inflammation in subjects with HIV disease. Clin Infect Dis. 2008;46:775-780. (Pubitemid 351321565)
11. Ross AC, Rizk N, O'Riordan MA, et al. Relationship between inflammatory markers, endothelial activation markers, and carotid intima-media thickness in HIV-infected patients receiving antiretroviral therapy. Clin Infect Dis. 2009;49:1119-1127.
12. Cooke JP. ADMA: its role in vascular disease. Vasc Med. 2005; 10(suppl 1):S11-S17. (Pubitemid 43137263)
13. Antoniades C, Bakogiannis C, Tousoulis D, et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54:669-677.
14. Blann AD, Nadar SK, Lip GY. The adhesion molecule P-selectin and cardiovascular disease. Eur Heart J. 2003;24:2166-2179. (Pubitemid 37522669)
15. Schafer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis.Curr Vasc Pharmacol. 2008;6:52-60.
16. El-Sadr WM, Lundgren JD, Neaton JD, et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med. 2006;355:2283-2296. (Pubitemid 44837777)
17. Emery S, Neuhaus J, Phillips A, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197:1133-1144. (Pubitemid 351590049)
18. Ardigo D, Stuehlinger M, Franzini L, et al. ADMA is independently related to flow-mediated vasodilation in subjects at low cardiovascular risk. Eur J Clin Invest. 2007;37:263-269. (Pubitemid 46439414)
19. Schwedhelm E, Xanthakis V, Maas R, et al. Asymmetric dimethylarginine reference intervals determined with liquid chromatography-tandem mass spectrometry: results from the Framingham offspring cohort. Clin Chem. 2009;55:1539-1545.
20. Sydow K, Fortmann SP, Fair JM, et al. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities.Clin Chem. 2010;56:111-120.
21. Iribarren C, Husson G, Sydow K, et al. Asymmetric dimethyl-arginine and coronary artery calcification in young adults entering middle age: the CARDIA Study. Eur J Cardiovasc Prev Rehabil. 2007;14:222-229. (Pubitemid 46650077)
22. Schulze F, Maas R, Freese R, et al. Determination of a reference value for N(G), N(G)-dimethyl-L-arginine in 500 subjects. Eur J Clin Invest. 2005; 35:622-626. (Pubitemid 41406726)
23. Boger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592-1600.
24. Leong T, Zylberstein D, Graham I, et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol. 2008; 28:961-967. (Pubitemid 351544114)
25. Torriani FJ, Komarow L, Parker RA, et al. Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: the ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol.2008;52:569-576.
26. Solages A, Vita JA, Thornton DJ, et al. Endothelial function in HIVinfected persons. Clin Infect Dis. 2006;42:1325-1332.
27. Jang JJ, Berkheimer SB, Merchant M, et al. Asymmetric dimethylarginine and coronary artery calcium scores are increased in patients infected with human immunodeficiency virus. Atherosclerosis. 2011; 217:514-517.
28. Kurz K, Teerlink T, Sarcletti M, et al. Plasma concentrations of the cardiovascular risk factor asymmetric dimethylarginine (ADMA) are increased in patients with HIV-1 infection and correlate with immune activation markers. Pharmacol Res. 2009;60:508-514.
29. Hennekens CH, Schneider WR, Pokov A, et al. A randomized trial of aspirin at clinically relevant doses and nitric oxide formation in humans.J Cardiovasc Pharmacol Ther. 2010;15:344-348.
30. Satchell CS, Cotter AG, O'Connor EF, et al. Platelet function and HIV: a case-control study. AIDS. 2010;24:649-657.
31. Holme PA, Muller F, Solum NO, et al. Enhanced activation of platelets with abnormal release of RANTES in human immunodeficiency virus type 1 infection. FASEB J. 1998;12:79-89.
32. Corrales-Medina VF, Simkins J, Chirinos JA, et al. Increased levels of platelet microparticles in HIV-infected patients with good response to highly active antiretroviral therapy. J Acquir Immune Defic Syndr.2010;54:217-218.
33. Zetterberg E, Neuhaus J, Baker JV, et al. Kinetics of platelet counts following interruption of ART: results from the SMART Study. Paper presented at: 18th Conference on Retroviruses and Opportunistic Infections (CROI); February 2011; Boston, M.A.
34. Wolf K, Tsakiris DA, Weber R, et al. Antiretroviral therapy reduces markers of endothelial and coagulation activation in patients infected with human immunodeficiency virus type 1. J Infect Dis. 2002; 185:456-462. (Pubitemid 34142807)
35. Heeschen C, Dimmeler S, Hamm CW, et al. Soluble CD40 ligand in acute coronary syndromes. N Engl J Med. 2003;348:1104-1111. (Pubitemid 36337321)
36. Antoniades C, Bakogiannis C, Tousoulis D, et al. The CD40/CD40 ligand system: linking inflammation with atherothrombosis. J Am Coll Cardiol. 2009;54:669-677.
37. McEver RP. Adhesive interactions of leukocytes, platelets, and the vessel wall during hemostasis and inflammation. Thromb Haemost. 2001; 86:746-756. (Pubitemid 32834182)
38. Chougnet C. Role of CD40 ligand dysregulation in HIV-associated dysfunction of antigen-presenting cells. J Leukoc Biol. 2003; 74:702-709. (Pubitemid 38040346)
39. Baum PD, Sullam PM, Stoddart CA, et al. Abacavir increases platelet reactivity via competitive inhibition of soluble guanylyl cyclase. AIDS 2011;25:2243-2248.